

Brookings Council on Antibacterial Drug Development Meeting #1

The Brookings Institution • Washington, DC

Thursday, August 30, 2012

Participant List

Paul Ambrose

President, Institute for Clinical
Pharmacodynamics and Honorary Research
Professor, University of Oxford College of
Medicine

Danny Benjamin

Professor of Pediatrics and Faculty Associate
Director, Duke Clinical Research Institute, Duke
University School of Medicine

John Bradley

Professor and Chief, Division of Infectious
Diseases, Department of Pediatrics, University of
California, San Diego, School of Medicine and
Director, Division of Infectious Diseases, Rady
Children's Hospital San Diego

Robert Califf

Vice Chancellor for Clinical and Translational
Research, Director of the Duke Translational
Medicine Institute, Duke University Medical
Center

Deborah Collyar

President, Patient Advocates In Research

Heather Colvin

Senior Research Associate, Engelberg Center for
Health Care Reform, The Brookings Institution

Allan Coukell

Director, Medical Programs, Pew Health Group,
The Pew Charitable Trusts

Edward Cox

Director, Office of Antimicrobial Products,
Center for Drug Evaluation and Research,
U.S. Food and Drug Administration

Ralph D'Agostino

Chairman, Mathematics and Statistics
Department, and Professor of
Mathematics/Statistics, Biostatistics, and
Epidemiology, Boston University

Gregory Daniel

Managing Director and Fellow, Engelberg Center
for Health Care Reform, The Brookings Institution

Robert Danner

Senior Investigator and Head, Infectious Diseases
Section, Critical Care Medicine Department,
National Institutes of Health Clinical Center

Dennis M. Dixon

Chief, Bacteriology and Mycology Branch,
National Institute of Allergy and Infectious
Disease, National Institutes of Health

Mike Dudley

Senior Vice President, Research & Development
and Chief Scientific Officer, Rempex
Pharmaceuticals, Inc.

Michael Dunne

Chief Medical Officer, Durata Therapeutics

Barry Eisenstein

Senior Vice President of Scientific Affairs, Cubist
Pharmaceuticals and Clinical Professor of
Medicine, Harvard Medical School

John Farley

Deputy Director, Office of Antimicrobial Products,
Center for Drug Evaluation and Research, U.S.
Food and Drug Administration

Thomas Fleming

Professor, Department of Biostatistics,
University of Washington School of Public Health

Vance Fowler Jr.

Professor, Department of Medicine – Infectious
Diseases, Duke University

David Friedland

Vice President, Clinical Sciences, Cerexa, Inc.

David N. Gilbert

Chief of Infectious Diseases and Director, Earle A. Chiles Research Institute, Providence Portland Medical Center and Professor of Medicine, Oregon Health and Sciences University

Mark Goldberger

Divisional Vice President, Regulatory Policy and Intelligence, Abbott Pharmaceuticals

Mohammad Huque

Director, Division of Biometrics IV, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Dmitri Iarikov

Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Audrey Jackson

Senior Program Officer, Science and Research, Infectious Diseases Society of America

John Jenkins

Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Larry Kocot

Deputy Director, Engelberg Center for Health Care Reform, Visiting Fellow, Economic Studies, The Brookings Institution

Katie Laessig

Deputy Director, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Joe Larsen

Chief, Broad Spectrum Antimicrobials (BSA) Program, Division of CBRN Medical Countermeasures, Biomedical Advanced Research and Development Authority

Lisa LaVange

Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Dara Lieberman

Senior Government Relations Manager, Trust for America's Health

Ben Lorenz

Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Mark McClellan

Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies, and Leonard D. Schaeffer Chair in Health Policy Studies, The Brookings Institution

Kunal Merchant

Senior Clinical Project Manager, Clinical Trials Transformation Initiative

Bob Meyer

Vice President, Global Regulatory Strategy, Policy and Safety, Merck

Theresa Mullin

Director, Office of Planning and Informatics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Sumati Nambiar

Deputy Director for Safety, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Kevin Outterson

Associate Professor of Health Law, Bioethics and Human Rights, Boston University School of Law

John Powers

Senior Medical Scientist, Science Applications International Corporation in support of the National Institute of Allergy and Infectious Diseases, National Institutes of Health and Associate Clinical Professor of Medicine, George Washington University School of Medicine

Charlene Reed

Founder and Chief Executive Officer, Foundation to Combat Antimicrobial Resistance

John Rex

Infection Clinical Vice President, AstraZeneca Pharmaceuticals and Adjunct Professor of Medicine, University of Texas Medical School at Houston

Kellie Schoolar Reynolds

Deputy Division Director, Division of Clinical Pharmacology IV, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Louis Rice

Chair, Department of Medicine, Warren Alpert Medical School of Brown University and Physician-in-Chief, Rhode Island Hospital and The Miriam Hospital

Melissa Robb

Associate Director for Regulatory Affairs, Office of Medical Policy Initiatives, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Leonard Sacks

Associate Director for Clinical Methodology, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jonas Santiago

Analyst, Division of Medical Policy Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Rachel Sherman

Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

David Shlaes

Sole Proprietor and President, Anti-Infectives Consulting

Tom Smith

Lead Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Brad Spellberg

Associate Professor of Medicine, Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

George Talbot

Principal, Talbot Advisors LLC

Bob Temple

Deputy Center Director for Clinical Science and Acting Deputy Director of the Office of Drug Evaluation I (ODE-I), Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Pamela Tenaerts

Executive Director, Clinical Trials Transformation Initiative

Jeanine Thomas

President and Founder, MRSA Survivors Network

Joe Toerner

Associate Director for Medical Affairs, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

John Tomayko

Senior Medical Director, GlaxoSmithKline

Janet Woodcock

Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration